abstract |
The present invention generally relates to chemotherapeutic treatment of proliferative disorders, such as cancer. The invention more specifically relates to inhibition of pan-cell cycle progression with alkylating anthraquinones, which may inhibit mitotic commitment, lead to limited expression of G2 arrest and force cells to enter polyploidy via an aberrant mitosis. The methods of the invention are particularly useful in the treatment of chemotherapy-resistant cancers. |